Human papillomavirus type 16 antigenic epitopes (HPV-16 epitopes)

Human papillomavirus type 16 (HPV-16) antigenic epitopes are specific molecular regions of the virus, primarily derived from the L1 major capsid protein and the E6 and E7 oncoproteins, that are recognized by the host immune system (Doorbar et al., 2012, Vaccine). HPV-16 is the most prevalent high-risk HPV type, responsible for approximately 50% of cervical cancers and a significant portion of other anogenital and oropharyngeal malignancies (National Cancer Institute, 2023). The L1 protein epitopes are the primary targets for prophylactic vaccines, which induce neutralizing antibodies to prevent viral infection (FDA, Gardasil 9 Label). In contrast, the E6 and E7 proteins are constitutively expressed in HPV-transformed cells and serve as critical targets for therapeutic vaccines designed to stimulate T-cell-mediated destruction of cancerous or precancerous cells (Yang et al., 2016, Frontiers in Immunology). Drugs targeting these epitopes include widely used preventive vaccines like Gardasil 9 and experimental immunotherapies such as VGX-3100 (ClinicalTrials.gov). These epitopes are essential for both the prevention of infection and the treatment of established HPV-driven malignancies.

Other names

HPV16 antigensHPV-16 E6/E7 epitopesHPV-16 L1/L2 epitopesHuman papillomavirus 16 proteins

Prophylactic vaccines utilize virus-like particles (VLPs) to induce neutralizing antibodies against the L1 capsid protein, preventing viral attachment and entry. Therapeutic vaccines target the E6 and E7 oncoproteins to stimulate CD8+ cytotoxic T-cell and CD4+ helper T-cell responses, aiming to eliminate HPV-infected or malignant cells.